NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most ...

Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment.

Vertex SME Holdings Limited, a private equity vehicle managed by JMMB Securities Limited, is gearing up to raise another $1 billion to fund its pipeline of investment opportunities. Private equity ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial market ...

Google’s Veo 3 AI video generating software is now available to try in Vertex AI in public preview - here’s what you need to know.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Mid-gestation assessment of the risk for small for gestational age can help identify pregnancies needing additional monitoring beyond routine care, improving outcomes for those at high risk.

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Exclusive collaboration and license agreement for povetacicept in ...

Dental pain is a common symptom during pregnancy. Learn more about the possible causes and how to manage them here.

Maternal infections underlie several adverse birth outcomes. Whether trimethoprim–sulfamethoxazole prophylaxis during pregnancy will improve birth outcomes is unknown. In a double-blind ...